Novel viruses eyed to break through gene therapy's limits; new hazards for clinical research in the Dobbs era

The hope is that nature's nanoscale menagerie can be used to solve the safety, durability, and capacity issues in the gene therapy field. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      In the fiercely competitive world of health care, blockchain technology is quickly becoming the next frontier. Get up to speed with our latest STAT Report, a guide to blockchain in health care. STAT+: Biotech turns to new and strange viruses to overcome gene therapy's limitations By Jason Mast CDC via AP The hope is that nature’s nanoscale menagerie can be used to solve the safety, durability, and capacity issues in the gene therapy field. Read More Opinion: Subject, not suspect: The new hazards of conducting clinical research in the Dobbs era By Aoife Brennan Molly Ferguson for STAT Criminalizing women for their reproductive health choices raises serious issues for clinical research in states that restrict abortion. Read More STAT+: Health insurers are painting a misleading picture of Medicare Advantage savings, experts say By Bob Herman Adobe A new report funded by the insurance industry claims Medicare Advantage saves taxpayers “billions of dollars.” Experts don’t buy it. Read More Sponsor content by CSL Seqirus The burden of seasonal influenza on our communities While influenza is often seen as a respiratory disease that resolves on its own, it can come with broader health and non-medical consequences. In a future where co-circulation of COVID-19 and influenza is likely, it is more important than ever that people take influenza seriously. Learn more about seasonal influenza and its burden on our communities. Opinion: FDA: Ignore a pharma company's deceptive racial equity argument for keeping Makena, an ineffective preterm labor drug By Adam C. Urato Adobe A pharma company is arguing that Makena should be kept on the market because it may work in Black people. But it doesn't work in any people. Read More STAT+: Some European regulators are starting to take steps to ensure clinical trial results are reported By Ed Silverman Adobe Regulators in half a dozen European countries are now taking steps to enforce requirements that clinical trial sponsors make results public. Read More Monday, September 26, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser